Series on Cancer Therapy

Check out our Series of Review articles on emerging concepts in cancer therapy, novel therapeutic approaches and the challenges in translating preclinical work to the clinic. 

Announcements

  • We are looking for a dynamic, motivated scientist with a strong background in any area of cancer research, including cancer biology, immunology, genomics, translational & clinical research, to join our team as an Associate or Senior Editor.

  • Section of the March 2020 Nature Cancer cover, in which this project was launched.

    Our Series of commissioned Reviews covers the impact of genomics in guiding cancer diagnosis and treatment, the role of emerging technologies, and efforts toward translating new discoveries to the clinic.

  • Emerging therapeutic approaches in cancer image

    Register for our free webinar focusing on emerging therapeutic approaches in cancer, with Drs Haidong Dong, Adrian Harris, Jan-Paul Medema, Yi-Long Wu and our Chief Editor Alexia-Ileana Zaromytidou discussing the latest developments and ongoing challenges in cancer therapy | Thursday 24th June, 8-9.30 am (EDT), 2-3.30 pm (CET), 8-9.30 pm (CST)

  • Connected Network picture by Alamy, cover for the Cancer Milestone on "The AI revolution in Cancer"

    View our webinar on "The AI Revolution in Cancer", exploring recent advances on digital histopathology and Artificial Intelligence to predict molecular features and patient prognosis pan-cancer, with Dr. Jakob N. Kather (Aachen University) and Dr. Moritz Gerstung (EMBL-EBI), with a follow-up Q&A session moderated by Dr. Miguel Foronda (Nature Cancer). Free registration.

Nature Cancer is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.

Advertisement

    • Despite substantial advances in understanding of the molecular features of gliomas, the therapeutic options for these aggressive tumors remain scarce. Rich, Mitchell and colleagues provide their views about a phase 1 clinical trial testing the safety and efficacy of vaccines against cancer expressing mutant metabolic enzyme IDH1 in patients with high-grade glioma.

      • Sameer Agnihotri
      • Kailin Yang
      • Jeremy N. Rich
      Cancer in Translation
    • FTO, an m6A RNA demethylase, is known mainly as an oncoprotein in various cancer types. FTO is now shown to act as a cancer suppressor in a subset of epithelial tumors through an interplay between epithelial-to-mesenchymal transition and Wnt signaling.

      • Albertas Navickas
      • Hani Goodarzi
      News & Views
    • The DNA polymerase Polθ is synthetic lethal with homologous-recombination deficiency, but a lack of specific targeting compounds has limited its therapeutic potential. Two studies now describe first-in-class inhibitors of Polθ with in vivo efficacy and thus provide alternative therapeutic approaches to PARP inhibitors for cancers deficient in homologous recombination.

      • Thomas Helleday
      News & Views
    • Scatiltri and colleagues review the paradigms of targeting PI3K in solid tumors in the clinic, including the progress so far in developing effective inhibitors as well as clinical limitations due to toxicity and therapeutic resistance.

      • Pau Castel
      • Eneda Toska
      • Maurizio Scaltriti
      Review Article
    • Mutations in genes encoding epigenetic modifiers are frequent in acute myelogenous leukemia (AML) and have been proposed to cause AML via activation of oncogenes and repression of tumor suppressors. Two studies now identify unexpected oncogenic mechanisms and therapeutic vulnerabilities in AML arising from mutations in genes encoding the epigenetic regulators DNMT3A and ASXL1.

      • Koki Ueda
      • Ulrich Steidl
      News & Views
  • Social media have emerged as a key communication tool for scientists. Here we explore how to reap the benefits and avoid the pitfalls of social networking.

    Editorial
  • The treatment of triple-negative breast cancer remains chemotherapy based and lacks targeted drugs. However, immunotherapy combinations have shown promising activity, targeted chemotherapy options via antibody–drug conjugates are in the clinic, and molecular means of identifying targetable subsets are on the horizon. This Clinical Outlook discusses current and future possibilities for treating triple-negative breast cancer.

    • Lisa A. Carey
    Clinical Outlook
  • Making data available is essential for validating and furthering scientific discoveries. Helping authors navigate whether, how and in what form to share the data is also essential.

    Editorial
  • The COVID-19 pandemic is proving a major setback for achieving gender equality. Post-pandemic recovery efforts must focus on supporting diversity and bridging the gender gap.

    Editorial
  • The deployment of molecular biomarkers that are indicative of sensitivity to tumor-targeted or immune-targeted cancer therapies improves the outcome of individual patients and increases the chances of successful drug approval. However, for many lethal malignancies, the majority of clinical trials are conducted with patients who do not have biomarkers and hence they miss the target.

    • Jacob J. Adashek
    • Alexey Goloubev
    • Razelle Kurzrock
    Comment
Clinical Cancer Genomics

Clinical Cancer Genomics

Advances in sequencing and genomic technologies are rapidly expanding our understanding of cancer and in turn the role of genomics in clinical oncology.
Series